Pharmaceutical Technology

DECEMBER 5, 2022

Collectively, cannabinoid receptors (CB1 and CB2) are currently the most popular targets in preclinical stage of development, with 391 drugs tagged in total. In most EU and Commonwealth countries, including the UK, New Zealand and Australia, cannabinoids are legal for medical use.

Regulation 245

Regulation Drugs Development Marketing 245

pharmaphorum

APRIL 5, 2022

Immunocore now has approval on both side of the Atlantic for Kimmtrak – the first cancer therapeutic based on T cell receptor (TCR) technology – after getting a green light from the European Commission. Uveal melanoma is a rare cancer of the eye, which in the majority of patients is localised. ” Image by Pexels from Pixabay

Protein 52

Protein Sales Drugs Trials 52

pharmaphorum

DECEMBER 23, 2022

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. These are particularly important in the progression of certain blood cancers.

Development 52

Development Drugs Clinical Development Antibody 52

XTalks

FEBRUARY 27, 2024

Melanoma is a type of skin cancer often caused by exposure to ultraviolet light, such as that from sunlight or indoor tanning. Despite accounting for only about one percent of all skin cancers, melanomas make up a significant proportion of cancer-related deaths. The cost is the highest of any cell-based cancer drug in the US.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

XTalks

AUGUST 19, 2022

XTALKS WEBINAR: How Agile Clinical Trials Unlock Universal Access to Rare Disease Research. Live and On-Demand: Tuesday, October 4, 2022, at 11am EDT (4pm BST/UK). Zynteglo’s hefty price tag of $2.8 The FDA also had to weigh the benefit of the therapy against the risk that it may cause cancer.

Gene Therapy 95

Gene Therapy FDA Approval Gene Clinical Trials 95

Drug Discovery World

NOVEMBER 9, 2023

Novel platforms This session will begin with chariperson’s remarks from Lars Linden, PhD, Vice President, Head, Biologics Research, Bayer HealthCare, which will be followed by a keynote presentation by Agnieszka Kielczewska, PhD, Director, Research, Antibody Discovery and Screening, Biologics Discovery, Amgen.

Engineer 52

Engineer Antibody Protein In-Vivo 52

The Pharma Data

MARCH 20, 2021

Medicine in Oxford, Biogazelle, a biotechnology company in Ghent, and the Centre For Proteome Research at the University of Liverpool. Vandesompele is a research. professor in Functional Cancer Genomics and Applied. Manager, Weatherall Institute, Oxford UK. research efforts in further understanding viral-host.

Reagent 52

Reagent RNA Bioinformatics Medicine 52